Homology Medicines Inc. (NASDAQ: FIXX) open the trading on June 26, 2020, with a bit cautious approach as it glided -4.48% to $15.57. During the day, the stock rose to $16.65 and sunk to $15.48 before settling in for the price of $16.30 at the close. Taking a more long-term approach, FIXX posted a 52-week range of $11.05-$24.00.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -26.80%. This publicly-traded company’s shares outstanding now amounts to $45.15 million, simultaneously with a float of $42.77 million. The organization now has a market capitalization sitting at $736.93 million. At the time of writing, stock’s 50-day Moving Average stood at $14.39, while the 200-day Moving Average is $16.17.
Let’s gauge the efficiency of the firm, which has a total of 195 employees. It has generated 9 per worker during the last fiscal year. Meanwhile, its income per employee was -556. The stock had 8.33 Receivables turnover and 0.01 Total Asset turnover. For the Profitability, stocks operating margin was -6599.22 and Pretax Margin of -6237.45.
Homology Medicines Inc. (FIXX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Homology Medicines Inc.’s current insider ownership accounts for 0.50%, in contrast to 95.50% institutional ownership. According to the most recent insider trade that took place on Mar 17, this organization’s See Remarks sold 1,315 shares at the rate of 13.01, making the entire transaction reach 17,109 in total value, affecting insider ownership by 0. Preceding that transaction, on Feb 03, Company’s CFO, Treasurer & Secretary sold 12,000 for 16.16, making the whole transaction’s value amount to 193,866. This particular insider is now the holder of 0 in total.
Homology Medicines Inc. (FIXX) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 3/30/2020 suggests? It has posted -$0.78 earnings per share (EPS) not meeting the forecaster’s viewpoint (set at -$0.68) by -$0.1. This company achieved a net margin of -6237.45 while generating a return on equity of -45.86. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
Homology Medicines Inc.’s EPS decrease for this current 12-month fiscal period is -26.80% and is forecasted to reach -2.86 in the upcoming year.
Homology Medicines Inc. (NASDAQ: FIXX) Trading Performance Indicators
Let’s observe the current performance indicators for Homology Medicines Inc. (FIXX). It’s Quick Ratio in the last reported quarter now stands at 13.70. The Stock has managed to achieve an average true range (ATR) of 0.95. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 368.46.
In the same vein, FIXX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.62, a figure that is expected to reach -0.76 in the next quarter, and analysts are predicting that it will be -2.86 at the market close of one year from today.
Technical Analysis of Homology Medicines Inc. (FIXX)
[Homology Medicines Inc., FIXX] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 63.53% While, its Average True Range was 0.89.
Raw Stochastic average of Homology Medicines Inc. (FIXX) in the period of the previous 100 days is set at 36.36%, which indicates a major fall in contrast to 50.57% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 57.76% that was lower than 115.85% volatility it exhibited in the past 100-days period.